Saratoga Technologies Unveils FDA-Cleared Laserase, a Highly Useful 1927nm Thulium Laser System

Saratoga Technologies, L.L.C. launched Laserase™ on February 16, 2026 — an FDA-cleared laser system built around the 1927nm Thulium wavelength. The device is drawing serious attention from dermatologists who call this wavelength one of the most versatile tools in modern skin care, according to Access Newswire.
The 1927nm wavelength sits between low-impact and high-damage lasers. It creates tiny channels in the skin's surface — a process called micro-ablation — but leaves the outer skin layer intact. That means real results with just 24 to 72 hours of recovery time, compared to 10 to 14 days with traditional CO2 lasers, according to Financial Content.
The 1927nm wavelength absorbs water in skin tissue about 10 times more efficiently than the older 1550nm Er:Glass laser. But it is far gentler than the 10,600nm CO2 laser. This puts it in a precise middle zone — aggressive enough to improve pigmentation and stimulate collagen, but safe enough to use on patients with darker skin tones, according to Morningstar.
A 2025 review of 17 studies covering 448 patients found that 1927nm lasers significantly improved skin texture and pigmentation with a strong safety record. Clinical data also shows a 36.54% improvement in acne scarring — nearly equal to the 35.27% seen with more aggressive Er:YAG lasers. Patient satisfaction rates reach as high as 70% "satisfied or extremely satisfied," according to research cited by Joplin Globe.
Most competing laser devices charge clinics for disposable handpiece tips on every procedure. Saratoga Technologies built Laserase™ with a zero-consumable model — no per-procedure supplies needed. The company says clinics using this approach are seeing 3 to 5 times higher average revenue compared to standard microneedling treatments, according to Weatherford Democrat.
Jason Lake, President of Saratoga Technologies, said Laserase™ "elevates practices with transformative results and simplicity, expanding the clinical capabilities of thulium laser technology while remaining accessible and efficient." The Rockwall, Texas company was founded in 1994 and focuses on medical aesthetic devices that cut overhead for clinics, according to Corsicana Daily Sun.
The dermatology laser market is valued at $4.07 billion in 2026 and is growing at 7.8% per year, according to Precedence Research. The broader medical laser fiber market sits at $1.27 billion today and is projected to reach $4.2 billion by 2035. Multi-indication platforms — devices that treat many conditions at once — are driving that growth, according to Morningstar.
The FDA granted a "Substantially Equivalent" decision for the latest generation of powered laser surgical instruments in May 2026. This 510(k) clearance pathway lets manufacturers prove a new device is similar to an already-approved product — avoiding years of additional clinical trials required for higher-risk medical devices, according to Financial Content.
Not everyone agrees the 1927nm wavelength can do it all. Some surgeons say Thulium is a "polisher" — excellent for pigment and surface texture — but it cannot replace CO2 lasers for deep wrinkles and severe acne scars, which need what critics call "structural reconstruction." Researchers at the University of São Paulo also warn of "considerable variability in treatment parameters" and bias risk in early studies, according to Joplin Globe.
Melasma — a common skin pigmentation condition — can return after treatment. Recurrence rates range from 21.7% to 42%, meaning patients often need repeat sessions. Marketing materials emphasize that the laser is safe for all skin types, but clinical journals note that darker skin tones still require careful settings to avoid temporary redness and irritation, according to Corsicana Daily Sun.
Publishers
5
Articles
5
Reach
5